|
|
Jay D. Horton, Hitoshi Shimano, Robert L. Hamilton, Michael S. Brown, Joseph L. Goldstein
J Clin Invest. 1999;
103(7):1067
doi:10.1172/JCI6246
Abstract |
Full text
| PDF

T
ransgenic mice that overexpress the nuclear form of sterol regulatory element binding protein-1a (SREBP-1a) in liver (TgBP-1a mice) were shown previously to overproduce cholesterol and fatty acids and to accumulate massive amounts of cholesterol and triglycerides in hepatocytes. Despite the hepatic overproduction of lipids, the plasma levels of cholesterol (∼45 mg/dl) and triglycerides (∼55 mg/dl) were not elevated, perhaps owing to degradation of lipid-enriched particles by low-density lipoprotein (LDL) receptors. To test this hypothesis, in the current studies we bred TgBP-1a mice with LDL receptor knockout mice. As reported previously, LDLR–/– mice manifested a moderate elevation in plasma cholesterol (∼215 mg/dl) and triglycerides (∼155 mg/dl). In contrast, the doubly mutant TgBP-1a;LDLR–/– mice exhibited marked increases in plasma cholesterol (∼1,050 mg/dl) and triglycerides (∼900 mg/dl). These lipids were contained predominantly within large very-low-density lipoprotein (VLDL) particles that were relatively enriched in cholesterol and apolipoprotein E. Freshly isolated hepatocytes from TgBP-1a and TgBP-1a;LDLR–/– mice overproduced cholesterol and fatty acids and secreted increased amounts of these lipids into the medium. Electron micrographs of livers from TgBP-1a mice showed large amounts of enlarged lipoproteins within the secretory pathway. We conclude that the TgBP-1a mice produce large lipid-rich lipoproteins, but these particles do not accumulate in plasma because they are degraded through the action of LDL receptors.J. Clin. Invest. 103:1067–1076 (1999).
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal.
Not all publishers participate in CrossRef, so this information is not comprehensive.
Additionally, data may not reflect the most current citations to this article,
and the data may differ from citation information available from other sources
(for example, Google Scholar, Web of Science, and Scopus).
About CrossRef
| Title and authors |
Publication |
Year |
. |
Increased very low density lipoprotein (VLDL) secretion, hepatic steatosis, and insulin resistance
Sung Hee Choi, Henry N Ginsberg |
Trends Endocrin Met |
2011 |
.
|
LXRβ is required for glucocorticoid-induced hyperglycemia and hepatosteatosis in mice
Rucha Patel, Monika Patel, Ricky Tsai, Vicky Lin, Angie L. Bookout, Yuan Zhang, Lilia Magomedova, Tingting Li, Jessica F. Chan, Conrad Budd, David J. Mangelsdorf, Carolyn L. Cummins |
Journal Clinical Investigation |
2011 |
.
|
Obesity and nonalcoholic fatty liver disease: Biochemical, metabolic, and clinical implications
Elisa Fabbrini, Shelby Sullivan, Samuel Klein |
Hepatol |
2010 |
.
|
A steatosis kialakulásának patomechanizmusai
Péter Fülöp, György Paragh |
Orv Hetil |
2010 |
.
|
Hepatic insulin signaling regulates VLDL secretion and atherogenesis in mice
Seongah Han, Chien-Ping Liang, Marit Westerterp, Takafumi Senokuchi, Carrie L. Welch, Qizhi Wang, Michihiro Matsumoto, Domenico Accili, Alan R. Tall |
Journal Clinical Investigation |
2009 |
.
|
Syndecan-1 is the primary heparan sulfate proteoglycan mediating hepatic clearance of triglyceride-rich lipoproteins in mice
Kristin I. Stanford, Joseph R. Bishop, Erin M. Foley, Jon C. Gonzales, Ingrid R. Niesman, Joseph L. Witztum, Jeffrey D. Esko |
Journal Clinical Investigation |
2009 |
.
|
SR-BI protects against endotoxemia in mice through its roles in glucocorticoid production and hepatic clearance
Lei Cai, Ailing Ji, Frederick C. de Beer, Lisa R. Tannock, Deneys R. van der Westhuyzen |
Journal Clinical Investigation |
2008 |
.
|
The physiological and molecular regulation of lipoprotein assembly and secretion
Daniel A. Blasiole, Roger A. Davis, Alan D. Attie |
Mol Biosyst |
2007 |
.
|
Disruption of LDL but not VLDL clearance in autosomal recessive hypercholesterolemia
Christopher Jones, Rita Garuti, Peter Michaely, Wei-Ping Li, Nobuyo Maeda, Jonathan C. Cohen, Joachim Herz, Helen H. Hobbs |
Journal Clinical Investigation |
2007 |
.
|
Effect of polyunsaturated fatty acids on the expression of transcription factor adipocyte determination and differentiation-dependent factor 1 and of lipogenic and fatty acid oxidation enzymes in porcine differentiating adipocytes
J. M. Hsu, S. T. Ding |
BJN |
2007 |
.
|
SREBP-1c and TFE3, energy transcription factors that regulate hepatic insulin signaling
Hitoshi Shimano |
J Mol Med-JMM |
2007 |
.
|
Liver heparan sulfate proteoglycans mediate clearance of triglyceride-rich lipoproteins independently of LDL receptor family members
Jennifer M. MacArthur, Joseph R. Bishop, Kristin I. Stanford, Lianchun Wang, André Bensadoun, Joseph L. Witztum, Jeffrey D. Esko |
Journal Clinical Investigation |
2007 |
.
|
Diabetic dyslipidaemia
Martin Adiels, Sven-Olof Olofsson, Marja-Riitta Taskinen, Jan Borén |
Curr Opin Lipidol |
2006 |
.
|
SREBP-1: Gene Regulatory Key to Syndrome X?
DIRK MÜLLER-WIELAND, JÖRG KOTZKA |
Annals of the New York Academy of Sciences |
2006 |
.
|
Apolipoprotein B: a clinically important apolipoprotein which assembles atherogenic lipoproteins and promotes the development of atherosclerosis
S.-O. OLOFSSON, J. BOREN |
j int med |
2005 |
.
|
Oxidation, lipoproteins, and atherosclerosis: which is wrong, the antioxidants or the theory?
Kevin Jon Williams, Edward A Fisher |
Current Opinion in Clinical Nutrition and Metabolic Care |
2005 |
.
|
Sterol regulatory element-binding protein (SREBP)-1: gene regulatory target for insulin resistance?
Jorg Kotzka, Dirk Müller-Wieland |
eott |
2004 |
.
|
Monogenic hypercholesterolemia: new insights in pathogenesis and treatment
Daniel J. Rader, Jonathan Cohen, Helen H. Hobbs |
Journal Clinical Investigation |
2003 |
.
|
SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Jay D. Horton, Joseph L. Goldstein, Michael S. Brown |
Journal Clinical Investigation |
2002 |
.
|
Homocysteine-induced endoplasmic reticulum stress causes dysregulation of the cholesterol and triglyceride biosynthetic pathways
Geoff H. Werstuck, Steven R. Lentz, Sanjana Dayal, Gazi S. Hossain, Sudesh K. Sood, Yuan Y. Shi, Ji Zhou, Nobuyo Maeda, Skaidrite K. Krisans, M. Rene Malinow, Richard C. Austin |
Journal Clinical Investigation |
2001 |
.
|
|
|
|